Dipeptidyl peptidase-4 inhibitors and cardiovascular events in patients with type 2 diabetes, without cardiovascular or renal disease
Related Experiment Video
Updated: Dec 5, 2025

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory
Published on: February 28, 2013
Sheriza N Baksh1,2, Jodi B Segal1,2,3,4,5, Mara McAdams-DeMarco1,2
1Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States of America.
Background:
Cardiovascular safety of dipeptidyl peptidase-IV inhibitors (DPP-4i) in patients without cardiovascular or renal disease, a majority of newly diagnosed patients with type 2 diabetes often excluded from clinical trials on this association, is poorly understood. Thus, we investigate the risk of major adverse cardiovascular events (MACE) associated with DPP-4i in low-risk patients with diabetes.
Methods:
Using a new-user retrospective cohort derived from IBM MarketScan Commercial Claims and Encounters (2010-2015), we identified patients aged 35-65 with type 2 diabetes, without cardiovascular or renal disease, initiating DPP-4i, sulfonylureas, or metformin. Primary composite outcome of time to first MACE was defined as the first of any of the following: myocardial infarction, cardiac arrest, coronary artery bypass graft, coronary angioplasty, heart failure, and stroke. Secondary outcomes were time to first heart failure, acute myocardial infarction, and stroke. We compared outcomes for DPP-4i versus sulfonylurea and DPP-4i versus metformin using propensity score weighted Cox proportional hazards, adjusting for demographics, baseline comorbidities, concomitant medications, and cumulative exposure.
Results:
Of 445,701 individuals, 236,431 (53.0%) were male, median age was 51 (interquartile range: [44, 57]), 30,267 (6.79%) initiated DPP-4i, 52,138 (11.70%) initiated sulfonylureas, and 367,908 (82.55%) initiated metformin. After adjustment, DPP-4i was associated with lower risk of MACE than sulfonylurea (adjusted hazard ratio (aHR) = 0.87; 95% confidence interval (CI): 0.78-0.98), and similar risk to metformin (aHR = 1.07; 95% CI: 0.97-1.18). Risk for acute myocardial infarction (aHR = 0.70; 95% CI: 0.51-0.96), stroke (aHR = 0.57; 95% CI: 0.41-0.79), and heart failure (aHR = 0.57; 95% CI: 0.41-0.79) with DPP-4i was lower compared to sulfonylureas.
Conclusion:
Our findings show that for this cohort of low-risk patients newly treated for type 2 diabetes, DPP-4i exhibited 13% lower risk for MACE compared to sulfonylureas and similar risk for MACE compared to metformin, suggesting DPP-4i is a low cardiovascular risk option for low-risk patients initiating antihyperglycemic treatment.
Insights
Dipeptidyl peptidase-IV inhibitors (DPP-4i) show a 13% lower risk of major adverse cardiovascular events (MACE) compared to sulfonylureas in low-risk type 2 diabetes patients. DPP-4i offers similar MACE risk to metformin, indicating its safety for new antihyperglycemic treatment.
Area of Science:
- Endocrinology
- Cardiology
- Pharmacology
Background:
- Cardiovascular safety of DPP-4 inhibitors (DPP-4i) is unclear in newly diagnosed type 2 diabetes patients without existing cardiovascular or renal disease.
- These low-risk patients are often excluded from clinical trials, necessitating further investigation into MACE risks associated with DPP-4i.
Purpose of the Study:
- To investigate the risk of major adverse cardiovascular events (MACE) associated with DPP-4 inhibitors in low-risk type 2 diabetes patients.
- To compare the cardiovascular safety of DPP-4 inhibitors against sulfonylureas and metformin in this population.
Main Methods:
- A retrospective cohort study utilized IBM MarketScan data (2010-2015) of patients aged 35-65 with type 2 diabetes, initiating DPP-4i, sulfonylureas, or metformin.
- Propensity score weighting and Cox proportional hazards models were used to compare outcomes, adjusting for demographics, comorbidities, and medication exposure.
Main Results:
- DPP-4i use was associated with a lower risk of MACE compared to sulfonylureas (aHR=0.87) and a similar risk compared to metformin (aHR=1.07).
- Specific risks for acute myocardial infarction, stroke, and heart failure were lower with DPP-4i compared to sulfonylureas.
Conclusions:
- DPP-4 inhibitors demonstrate a favorable cardiovascular safety profile in low-risk type 2 diabetes patients initiating treatment.
- DPP-4i represents a safe antihyperglycemic treatment option with comparable MACE risk to metformin and lower risk than sulfonylureas.
Related Concept Videos
Dipeptidyl Peptidase 4 Inhibitors
Oral Hypoglycemic Agents: Biguanides and Glitazones
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
Acarbose and miglitol are...
Oral Hypoglycemic Agents: Glinides
Diabetes Mellitus: Type 2 and Gestational

